Stocks in play: Lexston Life Sciences

Announces that, on April 4, 2022, its wholly-owned subsidiary, Egret Bioscience Ltd., sponsored the whole genome sequencing, open access archiving and biobanking of the Pacific Northwest wood-rotting psychedelic mushroom, Psilocybe allenii. The “Allenii project” is a joint effort with the Entheome Foundation to sequence this species of psychedelic mushroom which was identified by modern science less than a decade ago in the Pacific Northwest. Lexston Life Sciences shares C.LEXT are trading unchanged at $0.03.

Read:

• Merger Arbitrage Opportunities Abound as Early 2022 M&A Activities Give Premium Prices

• Tech Innovation and Joint Efforts Needed for US to Achieve Energy Independence Once Again

• Increasing Domestic Oil Supplies Will Require Innovation and Group Efforts

• The M&A Flurry That Started in 2021 Isn’t Even Close to Done, According to Analysts

• Market Response to Oil and Gas Stocks Proving Energy Industry Can Still be ESG Friendly